Inovation capacity impact of the project results
The prepared nanoparticles from enzyme-responsive PIC particles for the delivery of antibiotic as Polymixin; last-resort antibiotics against multi-resistant s bacteria. These results will contribute to develop new tools to fight against antimicrobial resistance, one of the biggest medical challenges and a research priority for the European Commission (EC) this time.
The research results, we believe it can underpin future applications in both academia and industry, and therefore a future financial gain for the European Research Area (ERA). This technology potentially will be used for target other relevant infected bacteria. This programme had delivered unique world-leading research that will allow the development of functional nanomaterials that will be especially suited in the prevention and management of colonisation of wounds and medical surfaces by pathogenic bacteria in the next few years. This 2-year project led to very important scientific results that are under preparation for publishing in a high-quality scientific journal with open access.
Scientific and technological quality of the results
In details, we present nanoparticles particles as a specific delivery system for the antimicrobial antibiotics Polymyxin B with no need for any chemical modification. The prepared nanoparticles were degraded and release the antibiotic in a specific and selective way only in the presence of infections. This work had done in this project by the beneficiary and the supervisor will open a new way for a new type of antimicrobial materials that will help in fighting against these antibiotics resistances bacteria and decrease the possibility of resistance development to this antimicrobial formulation over time. As in this case, we had chosen P. aeruginosa; opportunistic pathogenic bacteria, known to commonly associated with more than 20% of hospital infections, able to be colonised in wounds and immunocompromised patients.